[2026-11-17] Anticholinergic Burden in Older Patients: An Exploratory Pilot Survey of Knowledge, Attitudes, and Practices Among Physicians in Taiwan
DOI:
https://doi.org/10.33165/rmj.2028.e282688Keywords:
Anticholinergic Burden, Older Adults, KAP framework, TaiwanAbstract
Background: Anticholinergic burden (ACB) is associated with adverse outcomes in older adults. In Taiwan, around 60% of adults aged 65 and over receive an anticholinergic medicine annually. Whether prescribers recognize this risk is unknown.
Objective: To describe physicians' knowledge, attitudes, and practices regarding ACB in older patients, and identify the resulting knowledge-practice gaps.
Methods: An anonymous online knowledge, attitudes and practices survey, used verbatim in English with permission from a UK study, was distributed to physicians at 92 Taiwanese hospitals (July 2024 and July-September 2025). Respondents aware of the term scored 10 medicines (0-3) against the ACB Calculator.
Results: Sixty-two physicians responded, 32 of them were emergency physicians. Only 14 (23%) were aware of the term. Among these 14, the mean number of medicines scored correctly was 1.9 of 10 (median [IQR], 0.5 [0.00-3.75]; range, 0-6), and 7 scored none correctly. Oxybutynin, the only medicine scoring 3, was correct in 2 of 14, while 7 answered 'do not know'. No respondent correctly classified all 10 medicines as having or lacking anticholinergic activity. Delirium was recognized by 6 of 14, but all 7 who answered selected urinary incontinence, which is not an anticholinergic adverse effect. Thirty-one of 60 (52%) rated assessment as important or very important, 23 were neutral, and 56 of 62 (90%) wanted further education. Of the 28 who prescribed anticholinergic medicines, 21 never calculated a burden score, 14 never considered ACB, and one did both routinely.
Conclusions: Most physicians were unaware of ACB and about half regarded it as important. Closing this gap will require education and prescribing decision support rather than awareness alone.
References
1. Suresh AV, Sargent P. Reducing anti-cholinergic burden in older patients. Clin Med. 2022;22(Suppl 4):75-76. doi:10.7861/clinmed.22-4-s75
2. Hilmer SN, Gnjidic D. The anticholinergic burden: from research to practice. Aust Prescr. 2022;45(4):118-120. doi:10.18773/austprescr.2022.031
3. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2
4. Grossi CM, Richardson K, Savva GM, et al. Increasing prevalence of anticholinergic medication use in older people in England over 20 years: cognitive function and ageing study I and II. BMC Geriatr. 2020;20(1):267. doi:10.1186/s12877-020-01657-x
5. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677
6. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-320. doi:10.2217/1745509X.4.3.311
7. Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6
8. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781-787. doi:10.1001/archinte.167.8.781
9. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-513. doi:10.1001/archinternmed.2007.106
10. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481-1486. doi:10.1177/0091270006292126
11. Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021;77(2):147-162. doi:10.1007/s00228-020-02994-x
12. King R, Rabino S. ACB Calculator. 3 July 2024. Accessed March 20, 2024. https://www.acbcalc.com
13. Lee CY, Cheng YD, Cheng WY, Tsai TH, Huang KH. The prevalence of anticholinergic drugs and correlation with pneumonia in elderly patients: a population-based study in Taiwan. Int J Environ Res Public Health. 2020;17(17):6260. doi:10.3390/ijerph17176260
14. Huang WC, Yang AS, Tsai DH, Shao SC, Lin SJ, Lai EC. Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study. BMJ. 2023;382:e076045. doi:10.1136/bmj-2023-076045
15. Liu YP, Chien WC, Chung CH, Chang HA, Kao YC, Tzeng NS. Are anticholinergic medications associated with increased risk of dementia and behavioral and psychological symptoms of dementia? A nationwide 15-year follow-up cohort study in Taiwan. Front Pharmacol. 2020;11:30. doi:10.3389/fphar.2020.00030
16. Phutietsile GO, Nishtala PS. Rethinking anticholinergic burden in older adults: innovative approaches to detection and management. Expert Rev Clin Pharmacol. 2025;18(8):551-562. doi:10.1080/17512433.2025.2546142
17. Dilokthornsakul P, Stewart C, Moss P, et al. Evaluating the anticholinergic burden in older patients: comprehensive insights from a nationwide survey among emergency medicine specialists in the UK. Geriatrics. 2025;10(6):137. doi:10.3390/geriatrics10060137
18. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
19. Launiala A. How much can a KAP survey tell us about people’s knowledge, attitudes and practices? Some observations from medical anthropology research on malaria in pregnancy in Malawi. Anthropol Matters. 2009;11(1):1-13. doi:10.22582/am.v11i1.31
20. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
21. Joint Commission of Taiwan. Taiwan Patient Safety Culture Survey Annual Report 2022. Joint Commission of Taiwan; 2023.
22. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372
23. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023-00777-y
24. Tiranaprakij P, Srisuma S, Putthipokin K, Ruangritchankul S. Anticholinergic burden and clinical outcomes among older adults admitted in a tertiary hospital: a prospective cohort study. PLoS One. 2025;20(9):e0332946. doi:10.1371/journal.pone.0332946
25. Royal College of Emergency Medicine. Emergency Medicine Curriculum 2021. Royal College of Emergency Medicine; 2021. Accessed 1 September 2026. https://rcem.ac.uk/em-curriculum
26. Bishara D, Harwood D, Sauer J, Taylor DM. Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. Int J Geriatr Psychiatry. 2017;32(6):650-656. doi:10.1002/gps.4507
27. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477-1483. doi:10.1111/j.1532-5415.2011.03491.x
28. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315. doi:10.1136/bmj.k1315
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 by the Author(s). Licensee RMJ.

This work is licensed under a Creative Commons Attribution 4.0 International License.





